
    
      The trial is a single center, placebo-controlled, double-blind, multiple-dose study in 2
      ascending dose cohorts of healthy subjects. The primary purpose of this study is to
      investigate the safety, tolerability and pharmacokinetic property of the multiple doses of
      TBN administered for 6.5 consecutive days in healthy participants.
    
  